The US Food and Drug Administration has approved Allergan’s and Gedeon Richter’s Vraylar (cariprazine) capsules, an oral atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.

Vraylar was discovered and co-developed by Gedeon Richter and was licensed to Actavis, now Allergan, in the US and Canada. Cariprazine is also being investigated for treating bipolar depression and as adjunctive treatment for major depressive disorder in adults.

Source: Allergan